BR112015022582A2 - molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo - Google Patents
molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeoInfo
- Publication number
- BR112015022582A2 BR112015022582A2 BR112015022582A BR112015022582A BR112015022582A2 BR 112015022582 A2 BR112015022582 A2 BR 112015022582A2 BR 112015022582 A BR112015022582 A BR 112015022582A BR 112015022582 A BR112015022582 A BR 112015022582A BR 112015022582 A2 BR112015022582 A2 BR 112015022582A2
- Authority
- BR
- Brazil
- Prior art keywords
- fmdv
- plasmid
- methods
- nucleic acid
- individual
- Prior art date
Links
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 239000013612 plasmid Substances 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/135—Foot- and mouth-disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Abstract
1 / 1 resumo âmolãcula de ãcido nucleico, plasmãdeo, vacina, e, mãtodos para gerar uma resposta imune contra fmdv em um indivãduo, para prevenir uma infecãão por fmdv em um indivãduo e para tratar um indivãduo que foi infectado com fmdvâ a presente invenã§ã£o se refere a proteãnas imunogãªnicas do vãrus da doenã§a da febre aftosa (fmdv) de consenso sintã©ticas e molã©cula de ã¡cido nucleico que codifica essas proteãnas, vacinas contra fmdv, mã©todos para induzir respostas imunes contra fmvd, mã©todos para distinguir entre indivãduos infectados com fmdv versus aqueles vacinados contra fmdv, e mã©todos de imunizar indivãduos de forma profilã¡tica e/ou terapãªutica contra fmdv.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361802225P | 2013-03-15 | 2013-03-15 | |
US201361794197P | 2013-03-15 | 2013-03-15 | |
US61/794,197 | 2013-03-15 | ||
US61/802,225 | 2013-03-15 | ||
PCT/US2014/030809 WO2014145951A2 (en) | 2013-03-15 | 2014-03-17 | Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112015022582A2 true BR112015022582A2 (pt) | 2017-10-24 |
BR112015022582B1 BR112015022582B1 (pt) | 2024-01-09 |
Family
ID=51538575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015022582-9A BR112015022582B1 (pt) | 2013-03-15 | 2014-03-17 | Molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo |
Country Status (11)
Country | Link |
---|---|
US (1) | US9993545B2 (pt) |
EP (2) | EP3756683A1 (pt) |
JP (4) | JP6817062B2 (pt) |
KR (3) | KR102276405B1 (pt) |
CN (2) | CN114045295A (pt) |
AU (1) | AU2014232363B2 (pt) |
BR (1) | BR112015022582B1 (pt) |
CA (1) | CA2895806C (pt) |
ES (1) | ES2817903T3 (pt) |
MX (2) | MX2015011487A (pt) |
WO (1) | WO2014145951A2 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9993545B2 (en) * | 2013-03-15 | 2018-06-12 | The Trustees Of The University Of Pennsylvania | Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom |
AR102547A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso |
EP3452068A4 (en) * | 2016-05-05 | 2020-01-22 | The Trustees of The University of Pennsylvania | FILOVIRUS-CONSENSUS-ANTIGENE, NUCLEIC ACID CONSTRUCTS AND VACCINES PRODUCED THEREOF, AND METHODS FOR USE THEREOF |
US10385319B2 (en) * | 2016-09-08 | 2019-08-20 | The Governement of the United States of America, as represented by the Secretary of Homeland Security | Modified foot-and-mouth disease virus 3C proteases, compositions and methods thereof |
US20190275138A1 (en) * | 2016-11-22 | 2019-09-12 | The Wistar Institute Of Anatomy And Biology | Foot and mouth disease virus serotype o (fmdv-o) vaccine |
WO2019132569A1 (ko) * | 2017-12-29 | 2019-07-04 | (주)플럼라인생명과학 | 구제역 바이러스 a형 백신 조성물 |
KR102165358B1 (ko) * | 2017-12-29 | 2020-10-14 | (주)플럼라인생명과학 | 구제역 바이러스 a형 백신 조성물 |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US21579A (en) | 1858-09-21 | Rotary valve fob steam-engines | ||
US5077044A (en) | 1980-05-19 | 1991-12-31 | The Board Of Trustees Of The Leland Stanford Jr. University | Novel non-reverting shigella live vaccines |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
ZA858044B (en) | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
US5643579A (en) | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
US5223424A (en) | 1985-09-06 | 1993-06-29 | Prutech Research And Development | Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence |
US4790987A (en) | 1985-11-15 | 1988-12-13 | Research Corporation | Viral glycoprotein subunit vaccine |
US5310668A (en) | 1986-06-20 | 1994-05-10 | Merck & Co., Inc. | Varicella-zoster virus as a live recombinant vaccine |
US5242829A (en) | 1986-09-23 | 1993-09-07 | Therion Biologics Corporation | Recombinant pseudorabies virus |
US5387744A (en) | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
US5294441A (en) | 1987-06-04 | 1994-03-15 | Washington University | Avirulent microbes and uses therefor: salmonella typhi |
IL86583A0 (en) | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
US5112749A (en) | 1987-10-02 | 1992-05-12 | Praxis Biologics, Inc. | Vaccines for the malaria circumsporozoite protein |
US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
DE4090351T1 (de) | 1989-03-08 | 1997-07-24 | Health Research Inc | Rekombinantes Pockenvirus-Wirtsselektionssystem |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
AU645489B2 (en) | 1989-03-31 | 1994-01-20 | Washington University | Vaccines containing avirulent phoP-type microorganisms |
ES2070997T3 (es) | 1989-12-04 | 1995-06-16 | Akzo Nobel Nv | Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos. |
US5294548A (en) | 1990-04-02 | 1994-03-15 | American Biogenetic Sciences, Inc | Recombianant Hepatitis a virus |
WO1991018088A1 (en) | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
US5462734A (en) | 1990-11-02 | 1995-10-31 | Wisconsin Alumni Research Foundation | Bovine herpesvirus vaccine and method of using same |
US5240703A (en) | 1991-03-01 | 1993-08-31 | Syntro Corporation | Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof |
US6034298A (en) | 1991-08-26 | 2000-03-07 | Prodigene, Inc. | Vaccines expressed in plants |
US5955088A (en) | 1992-02-03 | 1999-09-21 | Cedars-Sinai Medical Center | Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins |
EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
PT681483E (pt) | 1993-01-26 | 2005-11-30 | Wyeth Corp | Composicoes e metodos para distribuicao de material genetico |
US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
CA2164505A1 (en) | 1993-06-07 | 1994-12-22 | Phillip W. Berman | Hiv envelope polypeptides |
US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US6156319A (en) | 1994-07-25 | 2000-12-05 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex vaccine |
NL9401820A (nl) | 1994-11-02 | 1996-06-03 | Meyn Maschf | Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte. |
US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US5650309A (en) | 1995-05-16 | 1997-07-22 | The Regents Of The University Of California | Viral vectors |
US5698202A (en) | 1995-06-05 | 1997-12-16 | The Wistar Institute Of Anatomy & Biology | Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier |
DK1023107T3 (da) | 1997-04-03 | 2006-12-27 | Electrofect As | Fremgangsmåde til indgivelse af farmaceutiske præparater og nucleinsyrer i skeletmuskulaturen |
US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
HUP0004589A3 (en) | 1997-06-30 | 2003-08-28 | Centre Nat Rech Scient | Improved method for transferring nucleic acid into the striped muscle and combination therefor |
US6107021A (en) | 1998-06-20 | 2000-08-22 | United Biomedical, Inc. | Synthetic peptide vaccines for foot-and-mouth disease |
EP2428249B1 (en) | 1998-07-13 | 2015-10-07 | Inovio Pharmaceuticals, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
US6589529B1 (en) | 1998-10-30 | 2003-07-08 | Children's Hospital Medical Center | Rotavirus subunit vaccine |
WO2000056916A2 (en) | 1999-03-18 | 2000-09-28 | Exiqon A/S | Detection of mutations in genes by specific lna primers |
FR2810888B1 (fr) * | 2000-06-29 | 2004-07-30 | Merial Sas | Vaccin contre la fievre aphteuse |
JP3543326B2 (ja) | 2001-08-30 | 2004-07-14 | ソニー株式会社 | 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム |
US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
US20040175727A1 (en) | 2002-11-04 | 2004-09-09 | Advisys, Inc. | Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
WO2004085635A1 (en) | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | Melan-a peptide analogue-virus-like-particle conjugates |
EP2664672A1 (en) | 2003-04-17 | 2013-11-20 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
WO2004108260A2 (en) | 2003-05-30 | 2004-12-16 | Advisys, Inc. | Devices and methods for biomaterial production |
US7485291B2 (en) | 2003-06-03 | 2009-02-03 | Cell Genesys, Inc. | Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof |
US20050182005A1 (en) | 2004-02-13 | 2005-08-18 | Tuschl Thomas H. | Anti-microRNA oligonucleotide molecules |
EP1773387B1 (en) * | 2004-06-25 | 2013-06-12 | Merial Ltd. | Avipox recombinants expressing foot and mouth disease virus genes |
CN1737144A (zh) | 2004-08-18 | 2006-02-22 | 金宁一 | 口蹄疫复合多表位二价核酸疫苗的构建 |
EP1632247A1 (en) * | 2004-09-03 | 2006-03-08 | Consejo Superior De Investigaciones Cientificas | Nucleic acid sequences encoding FMDV proteins capable of associating into a virus-like particle |
WO2006063445A1 (en) | 2004-12-14 | 2006-06-22 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Recombinant foot and mouth disease vaccine |
CN100582122C (zh) * | 2006-05-12 | 2010-01-20 | 北京宝麦德生物医药科技有限责任公司 | O型口蹄疫病毒多表位粘膜免疫疫苗及其应用 |
CN101121938B (zh) | 2007-03-23 | 2010-10-06 | 中国农业科学院兰州兽医研究所 | 一种口蹄疫抗原的制备方法 |
WO2009073330A2 (en) | 2007-11-12 | 2009-06-11 | The Trustees Of The University Of Pennsylvania | Novel vaccines against multiple subtypes of influenza virus |
CN101270155B (zh) | 2008-05-06 | 2011-04-27 | 中国农业科学院兰州兽医研究所 | 通过耐酸性改造在昆虫中组装口蹄疫病毒空衣壳的方法 |
CN102712931A (zh) * | 2009-11-02 | 2012-10-03 | 宾夕法尼亚大学托管会 | 口蹄疫病毒病毒(fmdv)共有蛋白质、其编码序列及由其制备的疫苗 |
CN103492410A (zh) | 2010-03-12 | 2014-01-01 | 梅里亚有限公司 | 蓝舌病毒重组疫苗和其使用 |
US8765141B2 (en) * | 2010-07-01 | 2014-07-01 | The United States Of America, As Represented By The Secretary Of Agriculture | Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host |
GB201014965D0 (en) * | 2010-09-08 | 2010-10-20 | Animal Health Inst | Vaccine |
WO2013019603A2 (en) * | 2011-07-29 | 2013-02-07 | Inovio Pharmaceuticals, Inc. | Linear expression cassettes and uses thereof |
US9993545B2 (en) | 2013-03-15 | 2018-06-12 | The Trustees Of The University Of Pennsylvania | Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom |
-
2014
- 2014-03-17 US US14/774,356 patent/US9993545B2/en active Active
- 2014-03-17 AU AU2014232363A patent/AU2014232363B2/en active Active
- 2014-03-17 EP EP20173045.4A patent/EP3756683A1/en active Pending
- 2014-03-17 WO PCT/US2014/030809 patent/WO2014145951A2/en active Application Filing
- 2014-03-17 KR KR1020157028394A patent/KR102276405B1/ko active IP Right Grant
- 2014-03-17 CN CN202111424774.3A patent/CN114045295A/zh active Pending
- 2014-03-17 CA CA2895806A patent/CA2895806C/en active Active
- 2014-03-17 EP EP14765406.5A patent/EP2968519B1/en active Active
- 2014-03-17 BR BR112015022582-9A patent/BR112015022582B1/pt active IP Right Grant
- 2014-03-17 MX MX2015011487A patent/MX2015011487A/es active IP Right Grant
- 2014-03-17 KR KR1020237014180A patent/KR20230062666A/ko not_active Application Discontinuation
- 2014-03-17 ES ES14765406T patent/ES2817903T3/es active Active
- 2014-03-17 KR KR1020217021203A patent/KR20210088754A/ko not_active Application Discontinuation
- 2014-03-17 CN CN201480010741.6A patent/CN105338998B/zh active Active
- 2014-03-17 JP JP2016503467A patent/JP6817062B2/ja active Active
-
2015
- 2015-09-02 MX MX2020012913A patent/MX2020012913A/es unknown
-
2019
- 2019-04-04 JP JP2019072269A patent/JP6947773B2/ja active Active
-
2021
- 2021-05-06 JP JP2021078557A patent/JP7245282B2/ja active Active
-
2023
- 2023-03-09 JP JP2023036492A patent/JP2023063383A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2014145951A3 (en) | 2014-12-18 |
CN105338998A (zh) | 2016-02-17 |
JP2019141069A (ja) | 2019-08-29 |
CA2895806A1 (en) | 2014-09-18 |
AU2014232363A8 (en) | 2015-08-06 |
MX2015011487A (es) | 2016-02-03 |
EP3756683A1 (en) | 2020-12-30 |
ES2817903T3 (es) | 2021-04-08 |
CN114045295A (zh) | 2022-02-15 |
EP2968519A2 (en) | 2016-01-20 |
US9993545B2 (en) | 2018-06-12 |
JP6817062B2 (ja) | 2021-01-20 |
AU2014232363B2 (en) | 2017-03-02 |
KR20160002757A (ko) | 2016-01-08 |
KR102276405B1 (ko) | 2021-07-12 |
AU2014232363A1 (en) | 2015-07-16 |
JP7245282B2 (ja) | 2023-03-23 |
JP2023063383A (ja) | 2023-05-09 |
BR112015022582B1 (pt) | 2024-01-09 |
KR20230062666A (ko) | 2023-05-09 |
JP2021126118A (ja) | 2021-09-02 |
CN105338998B (zh) | 2021-12-14 |
JP2016515820A (ja) | 2016-06-02 |
WO2014145951A2 (en) | 2014-09-18 |
JP6947773B2 (ja) | 2021-10-13 |
KR20210088754A (ko) | 2021-07-14 |
MX2020012913A (es) | 2021-02-26 |
EP2968519B1 (en) | 2020-05-06 |
US20160045589A1 (en) | 2016-02-18 |
CA2895806C (en) | 2023-02-21 |
EP2968519A4 (en) | 2016-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
BR112017017949A2 (pt) | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna | |
BR112018013387A2 (pt) | vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit | |
EP4233898A3 (en) | Influenza mrna vaccines | |
BR112018017307A2 (pt) | molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus | |
MX2017009308A (es) | Composiciones inmunogenicas para usar en vacunas neumococicas. | |
BR112018004242A2 (pt) | composições de vacina que possuem estabilidade e imunogenicidade aumentadas | |
BR112015005987A2 (pt) | vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína | |
AR089797A1 (es) | Vacunas contra clostridum difficile que comprenden toxinas recombinantes | |
BRPI0923448A2 (pt) | vírus influenza rearranjado, composição antigênica de vírus influenza rearranjado, vacina, e, métodos para provocar uma resposta imune a pelo menos uma cepa pandêmica de vírus influenza em um indivíduo, para prevenir infecção de um indivíduo por um vírus influenza, e para preparar uma vacina. | |
CL2016002794A1 (es) | Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico | |
PE20151588A1 (es) | Vacuna contra el virus del dengue | |
BR112016015422A2 (pt) | formulações de vacina de frasco único | |
BRPI1007721B1 (pt) | composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66 | |
CL2017001961A1 (es) | Vacuna bivalente contra el virus de gripe porcina | |
CL2017003224A1 (es) | Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante | |
MX2015007753A (es) | Composicion de vacunas para sujetos intactos. | |
MY189495A (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
BR112014023414A2 (pt) | vacina de herpesvirus-1 equino recombinante contendo uma glicoproteína c mutante e seus usos | |
AR108829A1 (es) | Vacuna contra virus de bronquitis infecciosa | |
BR112017028212A2 (pt) | vacinação concomitante contra dengue e febre amarela | |
BR112016002354A2 (pt) | composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit | |
BR112016006210A2 (pt) | terapia e vacina contra gripe | |
BR112018015893A2 (pt) | vacinas de câncer e métodos de tratamento usando as mesmas | |
CO2022012272A2 (es) | Vacunas contra el coronavirus y métodos de uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023014258-6 PROTOCOLO 870230062188 EM 14/07/2023 17:21. |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/2014, OBSERVADAS AS CONDICOES LEGAIS |